[
  {
    "ts": "2025-10-20T21:50:02+00:00",
    "headline": "Merck (MRK) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.",
    "url": "https://finance.yahoo.com/news/merck-mrk-outpaces-stock-market-215002919.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "b731ff04-5a39-311e-801b-dca4de657215",
      "content": {
        "id": "b731ff04-5a39-311e-801b-dca4de657215",
        "contentType": "STORY",
        "title": "Merck (MRK) Outpaces Stock Market Gains: What You Should Know",
        "description": "",
        "summary": "Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.",
        "pubDate": "2025-10-20T21:50:02Z",
        "displayTime": "2025-10-20T21:50:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248",
          "originalWidth": 900,
          "originalHeight": 467,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EqfP7bv9QEr5Eo0h619oww--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248.cf.webp",
              "width": 900,
              "height": 467,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJLygzZiYik0.mXQcVdmSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-outpaces-stock-market-215002919.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-outpaces-stock-market-215002919.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T21:18:55+00:00",
    "headline": "Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint",
    "summary": "Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of",
    "url": "https://finance.yahoo.com/news/neuphoria-says-phase-3-trial-211855112.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c4fe06a2-f2f3-3bd9-8b2d-a55aeb188c9e",
      "content": {
        "id": "c4fe06a2-f2f3-3bd9-8b2d-a55aeb188c9e",
        "contentType": "STORY",
        "title": "Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint",
        "description": "",
        "summary": "Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of",
        "pubDate": "2025-10-20T21:18:55Z",
        "displayTime": "2025-10-20T21:18:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/neuphoria-says-phase-3-trial-211855112.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/neuphoria-says-phase-3-trial-211855112.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NEUP"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T21:12:30+00:00",
    "headline": "JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
    "summary": "Jamie Dimon is one of the highest-profile bankers in the world. Like Warren Buffett, David Solomon, or other Wall Street titans, when he speaks, people listen. Recently, the JPMorgan CEO called the three-year bull market run unmistakable, while warning that asset prices are currently high and credit spreads are unusually tight —a rough combination that ... JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
    "url": "https://247wallst.com/investing/2025/10/20/jpmorgan-says-correction-will-be-healthy-5-safe-high-yield-dividend-stocks/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9623f8c5-bd7f-38bb-a95e-2d2bd3a47faa",
      "content": {
        "id": "9623f8c5-bd7f-38bb-a95e-2d2bd3a47faa",
        "contentType": "STORY",
        "title": "JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
        "description": "",
        "summary": "Jamie Dimon is one of the highest-profile bankers in the world. Like Warren Buffett, David Solomon, or other Wall Street titans, when he speaks, people listen. Recently, the JPMorgan CEO called the three-year bull market run unmistakable, while warning that asset prices are currently high and credit spreads are unusually tight —a rough combination that ... JPMorgan Says Correction Will Be “Healthy” – 5 Safe High-Yield Dividend Stocks",
        "pubDate": "2025-10-20T21:12:30Z",
        "displayTime": "2025-10-20T21:12:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/55bd5686b0f4e738475c7bac7dac4ec8",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_6dHsKLMn7ejTKDWcSnK8Q--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/55bd5686b0f4e738475c7bac7dac4ec8.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WwRI4HUDNE8U.PRb8h_G7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/55bd5686b0f4e738475c7bac7dac4ec8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/10/20/jpmorgan-says-correction-will-be-healthy-5-safe-high-yield-dividend-stocks/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpmorgan-says-correction-healthy-5-211230979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDLZ"
            },
            {
              "symbol": "T"
            },
            {
              "symbol": "T-PA"
            },
            {
              "symbol": "ET"
            },
            {
              "symbol": "ET-PI"
            },
            {
              "symbol": "SUN"
            },
            {
              "symbol": "USAC"
            },
            {
              "symbol": "ETR"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T19:39:35+00:00",
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-193935061.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c5b4ec6c-54a2-37a6-b2b5-cc7ae99dfd41",
      "content": {
        "id": "c5b4ec6c-54a2-37a6-b2b5-cc7ae99dfd41",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Advance Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S",
        "pubDate": "2025-10-20T19:39:35Z",
        "displayTime": "2025-10-20T19:39:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-193935061.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-193935061.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CELC"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T17:59:46+00:00",
    "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
    "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the Health Car",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-175946695.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "4bfba3a5-5925-3df3-a8b1-72baa0f8a86d",
      "content": {
        "id": "4bfba3a5-5925-3df3-a8b1-72baa0f8a86d",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Advance Monday Afternoon",
        "description": "",
        "summary": "Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the Health Car",
        "pubDate": "2025-10-20T17:59:46Z",
        "displayTime": "2025-10-20T17:59:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-175946695.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-175946695.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BLCO"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T16:16:43+00:00",
    "headline": "Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys",
    "summary": "These five Goldman Sachs stock picks are poised for growth in 2026 and will continue to pay and raise their already significant and reliable dividends.",
    "url": "https://247wallst.com/investing/2025/10/20/goldman-sachs-reveals-sectors-with-top-2026-payouts-grab-5-strong-buys-now/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "109f4bd1-1da8-3522-b65b-264b16397df8",
      "content": {
        "id": "109f4bd1-1da8-3522-b65b-264b16397df8",
        "contentType": "STORY",
        "title": "Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys",
        "description": "",
        "summary": "These five Goldman Sachs stock picks are poised for growth in 2026 and will continue to pay and raise their already significant and reliable dividends.",
        "pubDate": "2025-10-20T16:16:43Z",
        "displayTime": "2025-10-20T16:16:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/e7099f4cae1dac564b217d956c13a77e",
          "originalWidth": 1344,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bdnv7S..UYqA2QPuTta1ew--~B/aD03Njg7dz0xMzQ0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/e7099f4cae1dac564b217d956c13a77e.cf.webp",
              "width": 1344,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mPmn6H_slGHO7eKwaKmIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/e7099f4cae1dac564b217d956c13a77e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/10/20/goldman-sachs-reveals-sectors-with-top-2026-payouts-grab-5-strong-buys-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/goldman-sachs-reveals-sectors-top-161643735.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LHX"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ES"
            },
            {
              "symbol": "AEP"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T16:11:26+00:00",
    "headline": "Top Midday Stories: Apple iPhone 17 Outsells Predecessor in US, China in First 10 Days; Amazon Web Services Outage Impacts Apps, Websites it Hosts",
    "summary": "All three major US stock indexes were up in midday trading Monday ahead of big-name earnings this we",
    "url": "https://finance.yahoo.com/news/top-midday-stories-apple-iphone-161126362.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "24de546b-87a9-3e2f-b942-ca4dbc1fb92c",
      "content": {
        "id": "24de546b-87a9-3e2f-b942-ca4dbc1fb92c",
        "contentType": "STORY",
        "title": "Top Midday Stories: Apple iPhone 17 Outsells Predecessor in US, China in First 10 Days; Amazon Web Services Outage Impacts Apps, Websites it Hosts",
        "description": "",
        "summary": "All three major US stock indexes were up in midday trading Monday ahead of big-name earnings this we",
        "pubDate": "2025-10-20T16:11:26Z",
        "displayTime": "2025-10-20T16:11:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-apple-iphone-161126362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-apple-iphone-161126362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "NFLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T14:10:00+00:00",
    "headline": "Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings",
    "summary": "ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",
    "url": "https://finance.yahoo.com/news/heres-expect-abbvies-oncology-segment-141000379.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "06f819ae-9015-3878-8716-7181eecf3a8a",
      "content": {
        "id": "06f819ae-9015-3878-8716-7181eecf3a8a",
        "contentType": "STORY",
        "title": "Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings",
        "description": "",
        "summary": "ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.",
        "pubDate": "2025-10-20T14:10:00Z",
        "displayTime": "2025-10-20T14:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-oncology-segment-141000379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-oncology-segment-141000379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T13:07:00+00:00",
    "headline": "2 Beaten-Down Stocks to Buy and Hold for the Next Decade",
    "summary": "That's plenty of time for these drugmakers to move past their challenges.",
    "url": "https://www.fool.com/investing/2025/10/20/2-beaten-down-stocks-to-buy-and-hold-for-the-next/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9a6717a0-6b95-36bd-adcf-4ea966679215",
      "content": {
        "id": "9a6717a0-6b95-36bd-adcf-4ea966679215",
        "contentType": "STORY",
        "title": "2 Beaten-Down Stocks to Buy and Hold for the Next Decade",
        "description": "",
        "summary": "That's plenty of time for these drugmakers to move past their challenges.",
        "pubDate": "2025-10-20T13:07:00Z",
        "displayTime": "2025-10-20T13:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e294b15cc2a6aad6f5faf4286866d54b",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Physician prescribing medicine to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IZR7TEmOnUDawWcdA9j6EA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e294b15cc2a6aad6f5faf4286866d54b.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/59DV72DVADskCk1ltwdwvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e294b15cc2a6aad6f5faf4286866d54b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/20/2-beaten-down-stocks-to-buy-and-hold-for-the-next/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-beaten-down-stocks-buy-130700314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T12:45:00+00:00",
    "headline": "KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)",
    "summary": "RAHWAY, N.J., October 20, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTRUDA as part of a neoadjuvant followed by adjuvant (perioperative) treatment regimen for patients with resectable NSCLC;",
    "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-demonstrates-long-term-124500817.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "9c0c787d-37aa-3c25-b8b0-f5070370e31f",
      "content": {
        "id": "9c0c787d-37aa-3c25-b8b0-f5070370e31f",
        "contentType": "STORY",
        "title": "KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)",
        "description": "",
        "summary": "RAHWAY, N.J., October 20, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTRUDA as part of a neoadjuvant followed by adjuvant (perioperative) treatment regimen for patients with resectable NSCLC;",
        "pubDate": "2025-10-20T12:45:00Z",
        "displayTime": "2025-10-20T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/2066c4c4692f1ef8d05e68a7e66c4946",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAO9VL520o8TwTdOOFjcdA--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2066c4c4692f1ef8d05e68a7e66c4946.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FjQN6xYZ7bXOjieJEGeg8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2066c4c4692f1ef8d05e68a7e66c4946.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-demonstrates-long-term-124500817.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/keytruda-pembrolizumab-demonstrates-long-term-124500817.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T10:48:58+00:00",
    "headline": "Merck breaks ground on $3B manufacturing plant in Virginia",
    "summary": "Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.",
    "url": "https://www.foxbusiness.com/markets/merck-breaks-ground-3b-manufacturing-plant-virginia",
    "source": "Fox Business",
    "provider": "yfinance",
    "raw": {
      "id": "dc339656-366c-3faf-85e4-31a9d7d5732f",
      "content": {
        "id": "dc339656-366c-3faf-85e4-31a9d7d5732f",
        "contentType": "STORY",
        "title": "Merck breaks ground on $3B manufacturing plant in Virginia",
        "description": "",
        "summary": "Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.",
        "pubDate": "2025-10-20T10:48:58Z",
        "displayTime": "2025-10-20T10:48:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fox_business_text_367/858b7de755d191a1c62d854937e472aa",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2rR5bTVvxlPm_DvpcfOjfg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/fox_business_text_367/858b7de755d191a1c62d854937e472aa.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PE6olJESF4DtnlMZTymbOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fox_business_text_367/858b7de755d191a1c62d854937e472aa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fox Business",
          "url": "https://www.foxbusiness.com/"
        },
        "canonicalUrl": {
          "url": "https://www.foxbusiness.com/markets/merck-breaks-ground-3b-manufacturing-plant-virginia",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-breaks-ground-3b-manufacturing-104858073.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T10:45:00+00:00",
    "headline": "Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
    "summary": "RAHWAY, N.J., October 20, 2025--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
    "url": "https://finance.yahoo.com/news/merck-breaks-ground-3-billion-104500630.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "d46c03ee-7f18-35d2-a354-dfee3c44e92a",
      "content": {
        "id": "d46c03ee-7f18-35d2-a354-dfee3c44e92a",
        "contentType": "STORY",
        "title": "Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
        "description": "",
        "summary": "RAHWAY, N.J., October 20, 2025--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia",
        "pubDate": "2025-10-20T10:45:00Z",
        "displayTime": "2025-10-20T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/0f96cdab06707c16a689d0d208c57c6f",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fgpLRrt7pbF0iXUG5SI_sg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0f96cdab06707c16a689d0d208c57c6f.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sEHCTzY40aBEHcso7GKqkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0f96cdab06707c16a689d0d208c57c6f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-breaks-ground-3-billion-104500630.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-breaks-ground-3-billion-104500630.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T09:13:27+00:00",
    "headline": "Summit’s dual-acting drug scores lung cancer win",
    "summary": "A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.",
    "url": "https://www.biopharmadive.com/news/summit-akeso-ivonescimab-harmoni6-lung-cancer-trial/803193/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "d2ba7154-bd15-39c3-975d-25d31c43debd",
      "content": {
        "id": "d2ba7154-bd15-39c3-975d-25d31c43debd",
        "contentType": "STORY",
        "title": "Summit’s dual-acting drug scores lung cancer win",
        "description": "",
        "summary": "A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.",
        "pubDate": "2025-10-20T09:13:27Z",
        "displayTime": "2025-10-20T09:13:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/34f837f16474ecfe619b5d965de3c0c7",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v9s4C.97Drs25ZTSWTOOTQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/34f837f16474ecfe619b5d965de3c0c7.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SPxPHgibEjWEzKuDvjtP_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/34f837f16474ecfe619b5d965de3c0c7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/summit-akeso-ivonescimab-harmoni6-lung-cancer-trial/803193/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/summit-dual-acting-drug-scores-091327542.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SMMT"
            },
            {
              "symbol": "9926.HK"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T06:50:00+00:00",
    "headline": "Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors",
    "summary": "BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, ...",
    "url": "https://finance.yahoo.com/news/transgene-bioinvents-armed-oncolytic-virus-065000643.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "610e4bea-d97c-3c43-9f8f-e10e0367d34f",
      "content": {
        "id": "610e4bea-d97c-3c43-9f8f-e10e0367d34f",
        "contentType": "STORY",
        "title": "Transgene and BioInvent's Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors",
        "description": "",
        "summary": "BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, ...",
        "pubDate": "2025-10-20T06:50:00Z",
        "displayTime": "2025-10-20T06:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cZ7nw0Tb4TK4YDcHOJ8wyw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7l7hY5scI.Njki1VTGiiQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/46e2cb332e043fe93eb50efbeae98e79.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/transgene-bioinvents-armed-oncolytic-virus-065000643.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/transgene-bioinvents-armed-oncolytic-virus-065000643.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BOVNF"
            },
            {
              "symbol": "TRGNF"
            },
            {
              "symbol": "BINV.ST"
            },
            {
              "symbol": "TNG.PA"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-20T06:30:00+00:00",
    "headline": "IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025",
    "summary": "Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone",
    "url": "https://finance.yahoo.com/news/io-biotech-presents-phase-3-063000555.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "220aa0ee-71f4-31a5-aeb9-506bbbed5464",
      "content": {
        "id": "220aa0ee-71f4-31a5-aeb9-506bbbed5464",
        "contentType": "STORY",
        "title": "IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025",
        "description": "",
        "summary": "Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone",
        "pubDate": "2025-10-20T06:30:00Z",
        "displayTime": "2025-10-20T06:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/5d564c2b31691d2f6edccac46f996d38",
          "originalWidth": 148,
          "originalHeight": 37,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qlCn5nIYyZSJjguoTKAGRg--~B/aD0zNzt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5d564c2b31691d2f6edccac46f996d38.cf.webp",
              "width": 148,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lg_1GZ3FB4Mmi2ESB2vcLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5d564c2b31691d2f6edccac46f996d38.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/io-biotech-presents-phase-3-063000555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/io-biotech-presents-phase-3-063000555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IOBT"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]